Actress Rumer Willis is utilizing ApoE genetic testing to assess her personal health risks. Her decision comes after her father, Bruce Willis, received a diagnosis of frontotemporal dementia.
Navigating the transition from aphasia to FTD
The impetus for Willis’s medical scrutiny is the degenerative brain disease affecting the 71-year-old Die Hard star. As the report notes, the Willis family first shared that Bruce Willis had been diagnosed with aphasia in 2022, a condition that impairs communication skills.
By February 2023, that diagnosis had progressed into frontotemporal dementia (FTD), a more severe condition that impacts cognitive function and behavior. This progression has fundamentally altered the family dynamic, moving Bruce's wife, Emma Heming Willis, into a primary caretaking role—a transition she documented in her book, The Unexpected Journey.
The "pretty average" results from Function testing
In a partnership with the health-tech company Function, Rumer Willis sought to quantify her own biological predispositions. According to the report, the 38-year-old actress received results that she characterized as "pretty average," indicating a moderate risk rather than an extreme certainty.
Willis intends to use this information as a form of "power" to guide her lifestyle choices. Rather than succumbing to the fear of the unknown, she is focusig on actionable preventative measures, specifically targeting heart health and the reduction of bodily inflammation to mitigate potential long-term risks .
A family history of diverse genetic concerns
The Willis family's health narrative is not limited to neurological issues. In an interview with People magazine, Rumer Willis noted that her family has faced various medical challenges, including instances of breast cancer among relatives.
This complex genetic landscape underscores why the actress views information as a tool for empowerment. By understanding her specific risks, she aims to avoid the "steep fall off the cliff" that can occur when health issues are left unmanaged in later years.
The missing data on the Willis sisters' health decisions
While the genetic testing provides a window into Alzheimer's risk,several specific details remain obscured. The report does not specify the exact level of risk identified by Function, nor does it clarify if the testing included other markers related to the family's history of breast cancer.
Furthermore, it remains unclear if Willis's sisters—Scout, Tallulah, or the younger Mabel and Evelyn—are pursuing similar diagnostic paths. The source focuses primarily on Rumer's individual proactive stance, leaving the broader family's medical strategy unexamined.
Comments 0